Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.

ABSTRACT:

Background

Trastuzumab and pertuzumab target the Human Epidermal growth factor Receptor 2 (HER2). Combination therapy has been shown to provide enhanced antitumour activity; however, the downstream signalling to explain how these drugs mediate their response is not clearly understood.

Methods

Transcriptome profiling was performed after 4 days of trastuzumab, pertuzumab and combination treatment in human ovarian cancer in vivo. Signalling pathways identified were validated and investigated in primary ovarian xenografts at the protein level and across a timeseries.

Results

A greater number and variety of genes were differentially expressed by the combination of antibody therapies compared with either treatment alone. Protein levels of cyclin-dependent kinase inhibitors

SUBMITTER: Sims AH 

PROVIDER: S-EPMC3364568 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature